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LAT: L-type amino acid transporter
L-Leu: L-leucine
mTOR: Mammalian target of rapamycin
NF-kB: Nuclear factor k-light-chain-enhancer of activated B cells
PI3K: Phosphatidylinositol 3-kinase
PMA: Phorbol 12-myristate 13-acetate
P-S6: Phospho-S6 ribosomal protein
RORgt: Retinoic acid receptor–related orphan receptor g
TCR: T-cell receptor
WT: Wild-type
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200 CIBRIAN ET ALBackground: Psoriasis is a frequent inflammatory skin disease
that is mainly mediated by IL-23, IL-1b, and IL-17 cytokines.
Although psoriasis is a hyperproliferative skin disorder, the
possible role of amino acid transporters has remained
unexplored.
Objective: We sought to investigate the role of the essential
amino acid transporter L-type amino acid transporter (LAT) 1
(SLC7A5) in psoriasis.
Methods: LAT1 floxed mice were crossed to Cre-expressing
mouse strains under the control of keratin 5, CD4, and retinoic
acid receptor–related orphan receptor g. We produced models
of skin inflammation induced by imiquimod (IMQ) and IL-23
and tested the effect of inhibiting LAT1 (JPH203) and
mammalian target of rapamycin (mTOR [rapamycin]).
Results: LAT1 expression is increased in keratinocytes and skin-
infiltrating lymphocytes of psoriatic lesions in human subjects
and mice. LAT1 deletion in keratinocytes does not dampen the
inflammatory response or their proliferation, which could be
maintained by increased expression of the alternative amino
acid transporters LAT2 and LAT3. Specific deletion of LAT1 in
gd and CD4 T cells controls the inflammatory response induced
by IMQ. LAT1 deletion or inhibition blocks expansion of IL-17–
secreting g41d41 and CD4 T cells and dampens the release of
IL-1b, IL-17, and IL-22 in the IMQ-induced model. Moreover,
inhibition of LAT1 blocks expansion of human gd T cells and
IL-17 secretion by human CD4 T cells. IL-23 and IL-1b
stimulation upregulates LAT1 expression and induces mTOR
activation in IL-171 gd and TH17 cells. Deletion or inhibition of
LAT1 efficiently controls IL-23– and IL-1b–induced
phosphatidylinositol 3-kinase/AKT/mTOR activation
independent of T-cell receptor signaling.
Conclusion: Targeting LAT1-mediated amino acid uptake is a
potentially useful immunosuppressive strategy to
control skin inflammation mediated by the IL-23/IL-1b/IL-17
axis. (J Allergy Clin Immunol 2020;145:199-214.)
Key words: L-type amino acid transporter 1, SLC7A5, psoriasis,
gd T cells, TH17, mammalian target of rapamycin
Psoriasis is a common skin disorder characterized by formation
of focal plaques of inflamed and raised skin with squamous
appearance.1 The affected portions of the skin show massive ker-
atinocyte proliferation and prominent infiltration of immune cells,
suggesting that psoriasis is a primary disorder of the skin immune
system.1-3 As in patients with other chronic inflammatory dis-
eases, the proinflammatory cytokines IL-23, IL-1b, and IL-17
exert important functions in patients with psoriasis.4-6
Human psoriatic skin showed increased numbers of IL-17–
releasing gd and TH17 cells,
7 as were also seen in murine models
induced by topical application of the Toll-like receptor 7/8 agonist
imiquimod (IMQ) or IL-23 injections.8-10 Increased numbers of
dermal macrophages, dendritic cells, and keratinocytes secreting
IL-1b and IL-23 are also described.8 IL-23 stimulates the survival
and proliferation of TH17 cells, whereas IL-1 receptor (IL-1R)–
deficient mice do not properly display TH17 cells.
11 However,
the molecular mechanism by which IL-23 receptor and IL-1R
contribute to the development, survival, and expansion of IL-17
cells remains unclear. Importantly, IL-1b potentiates the effects
of IL-23 by inducing expression of IL-23 receptor in both TH17
and gd T cells.11,12L-type amino acid transporter (LAT) 1 (SLC7A5) is a 512
amino acid–long, 12-transmembrane protein that mediates
sodium-independent large neutral amino acid transport.13 LAT1
(light chain) forms a heterodimeric complex with CD98/
SLC3A2 (heavy chain) through disulfide bonds.14 Heterodimeri-
zation stabilizes and enhances LAT1 transport to the plasma
membrane, making it fully functional.15 The alternative amino
acid transporters LAT2/SLC7A8, LAT3/SLC43A1, and LAT4/
SLC43A2 can also mediate large neutral amino acid uptake.16
However, LAT1 is the main L-leucine (L-Leu) transporter ex-
pressed in T-cell receptor (TCR)–activated T cells17 and natural
killer cells.18
The expression of LAT1 is increased in many cancer cells,19
including malignant skin lesions.20 LAT1 is the main mediator
of L-Leu uptake in malignant cells, and its usefulness as a target
to inhibit cancer proliferation has been explored. Accordingly, the
novel LAT1-specific inhibitor JPH203 has emerged as a prom-
ising cancer therapy that blocks the phosphatidylinositol 3-
kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway.21
Previously, we showed that CD69 regulates L-tryptophan
uptake through LAT1, which contributes to aryl hydrocarbon
receptor (AHR) activation in skin-resident gd T cells.22 In addi-
tion, LAT1 regulates L-Leu transport in CD4 T cells, controlling
mTOR activation induced by TCR signaling.17 However, a direct
contribution of LAT1 to skin inflammation in vivo remains
unexplored.
Here we use a conditional (floxed) LAT1 knockout mouse
(LAT1fl/fl)17 to assess the role of LAT1 in keratinocyte
proliferation and in CD4 and gd T-cell function in an in vivo
model of psoriasis induced by IMQ. Our results show that
LAT1 deletion does not affect keratinocyte proliferation, whereas
it effectively prevents expansion of IL-17–releasing immune
cells. The data herein demonstrate that LAT1 inhibition shuts
down the PI3K/AKT/mTOR axis induced by IL-23 and IL-1b
in immune cells, becoming a promising novel strategy to control
the inflammatory response that underlies the onset and course of
psoriasis.
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A complete and detailed description of the methods used in this study are
presented in the Methods section in this article’s Online Repository at www.
jacionline.org.Mice
LAT1 floxed mice have been previously described.17 CD4-Cre and reti-
noic acid receptor–related orphan receptor g (RORgt)–Cre mice were pur-
chased from the Jackson Laboratory (Bar Harbor, Me). Remaining mouse
strains, such as Krt5-CreERT2 mice, were kindly provided by different
groups.Human subjects
Skin punch biopsy specimens (3 mm) and blood samples were obtained
from patients with psoriasis and healthy volunteers. The study was approved
by the Hospital Universitario de La Princesa ethics committee, and all
participants provided written informed consent.Psoriasis model
IMQ-induced8,23 and an IL-23–induced22 murinemodels of skin inflamma-
tion were used, as described previously.Histologic analysis
Skin samples (from mice and human subjects) were processed for
hematoxylin and eosin (H&E) staining and analysis of LAT1, LAT2, LAT3,
and IL-17 expression by using immunohistochemical and immunofluores-
cence techniques.Flow cytometry analysis and in vitro stimulation
Single-cell suspensions from mouse skin, blood, and lymph nodes were
stained with a mixture of appropriate anti-mouse antibodies and analyzed
by using flow cytometry (FC) technique. Total PBMCs or purified CD4 T
cells from healthy donors and patients with psoriasis were also analyzed
by using FC after staining with corresponding antibodies (see Table E1 in
this article’s Online Repository at www.jacionline.org). The sequence of
used primers are listed in Table E2.
Human andmouse cell suspensions were in vitro stimulated with IL-23, IL-
1b, or both (10 ng/mL each) to analyze cytokine release (IL-17, IL-22, and
IFN-g), proliferation (Ki-67 and bromodeoxyuridine [BrdU]), and phospho-
S6 ribosomal protein (P-S6) expression.Amino acid assessments
The serum L-Leu profile of normal (wild-type [WT]) and Rag12/2 mice
treated or not with IMQ (for 5 days, 50 mg/d) were measured by using liquid
chromatography–tandem mass spectrometry.
Uptake of the 3H-radiolabeled amino acids L-phenylalanine and L-Leu
(PerkinElmer, Waltham, Mass) was assessed in activated CD4 T cells from
LAT1WT, LAT1DRgt, and LAT1DCD4 mice, according to the protocol described
previously.22Statistical analysis
Results were reported as mean 6 SEMs. Statistical evaluations were
performed with GraphPad Prism 7 software (GraphPad Software, La Jolla,
Calif). Normality of data distribution was assessed by using the
Kolmogorov-Smirnov test. The 2-tailed Student t test or Mann-Whitney
test was used for comparison of 2 populations. Multiple comparisons
were performed by using 1-way or 2-way ANOVA, followed by post
hoc (Bonferroni) tests. A P value of less than .05 was considered
significant.RESULTS
Expression of the essential amino acid transporter
LAT1 in psoriasis
To assess the relevance of essential amino acids in psoriasis, we
evaluated levels of L-Leu in normal (WT) and immunodeficient
(Rag12/2)mice treated or not with IMQ. Circulating levels of L-
Leu in Rag12/2mice were increased compared with those in WT
mice, suggesting that essential amino acids are likely modulated
by adaptive B or T cells in the IMQ model (Fig 1, A).
Normal skin is characterized by LAT2 expression, whereas
LAT1 mainly appears in several different types of malignant skin
lesions.24,25 Our results clearly showed that LAT1 expression is
induced in keratinocytes and lymphocytes in human psoriatic
skin (Fig 1, B and C), as well as in mouse skin after IMQ
application (Fig 1, D). Further analysis showed that dermal
IL-171 cells observed in mice treated with IMQ express LAT1
(Fig 1, E).
Considering the high expression of LAT1 in the epidermal
layer of patients with psoriasis, we examined the effect of deleting
LAT1 in keratinocytes. Mice carrying floxed LAT1 alleles
(LAT1fl/fl)17 were crossed with mice expressing the Cre
recombinase controlled by the keratinocyte-specific keratin 5
(K5) promoter (K5-CreERT2 mice)26 and Rosa26-floxed stop
tdTomato (Tm) mice.27 This system fluorescently labels the cells
that successfully underwent LAT1 deletion. After tamoxifen
administration, mice displaying fluorescently red skin from
both genotypes, LAT1WT and LAT1DK5, were selected for topical
treatment with IMQ. Both groups developed psoriasis after IMQ
application independent of LAT1 expression in keratinocytes
(Fig 2, A). The increase in epidermal thickness was similar in
both genotypes (Fig 2, B). Neutrophil and macrophage infiltration
also increased upon IMQ application independent of LAT1
expression in epidermal cells (Fig 2, C). Cre recombinase, as
determined by Tm expression, was not detected in inflammatory
cells (data not shown).
Analysis of Tm1 keratinocytes (CD49f1) confirmed deletion
of LAT1 expression after tamoxifen administration (Fig 2, D).
The proliferation markers Ki-67 and BrdU revealed that deletion
of LAT1 does not affect keratinocyte proliferation (Fig 2, E).
These results indicate that essential amino acid uptake in these
cells does not require LAT1 and could bemediated by other amino
acid transporters, such as LAT2 or LAT3, which can also shuttle
L-Leu.16 LAT2 is broadly expressed in keratinocytes in normal
human skin and increased in psoriatic lesions (see Fig E1, A, in
this article’s Online Repository at www.jacionline.org).
Epithelial cells, such as HaCat and Caco-2 cells, express LAT2
and LAT1, whereas Hela and lymphoid cells only express LAT1
(see Fig E1, B). Moreover, LAT2 expression in keratinocytes
increased in LAT1DK5 and LAT1WT mice after IMQ application
(see Fig E1, C). Finally, high expression of LAT3 was observed
in the basal layer of keratinocytes of normal human skin and
psoriatic lesions (see Fig E1,D). These data indicate that psoriasis
increases the expression of several essential amino acid
transporters in keratinocytes to support enhanced proliferation.
IL-171 secreting cells detected in the skin of IMQ-treated mice
are mainly Vg41d41 and CD4 T cells.28 Importantly, the
proliferative response of Vg41d41 (Fig 2, F) and CD4
(Fig 2, G) T cells induced in the draining lymph nodes after
IMQ application was similar in both mouse groups independent
of LAT1 expression in keratinocytes.
FIG 1. Expression of the amino acid transporter LAT1 is induced in patients with psoriasis and in the IMQ
model. A, Relative levels of L-Leu detected by using mass spectrometry in sera of healthy (Ctrl) and
IMQ-treated WT and Rag12/2 mice (n 5 4-6 mice). Bars indicate means 6 SEMs. ns, Not significant.
*P < .05, 2-tailed unpaired Student t test. B, LAT1 detection by means of immunohistochemistry in skin
biopsy specimens from healthy donors and patients with psoriasis. C, Representative immunofluorescence
of LAT1 (green) and CD3 (red) in skin samples from healthy donors and patients with psoriasis.
D, Immunofluorescence of LAT1 (green) and CD3 (red) in dorsal skin of WT mice after IMQ and control
skin. E, Detection of LAT1 (green) expression in dermal cells secreting IL-17 (red) in mice treated with
IMQ for 4 days. Zoom areas (left) are indicated by the white box (right). Nuclei were always stained with
49-6-diamidino-2-phenylindole dihydrochloride (DAPI; blue). Scale bars 5 100 and 50 mm in zoom area.
At least 3 skin biopsy specimens of mouse or human origin were simultaneously analyzed in each
experiment.
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FIG 2. Deletion of LAT1 in keratinocytes does not affect psoriasis induced by IMQ. A, Representative
pictures of LAT1WT and LAT1Dk5 mice after IMQ application. B, Representative H&E skin sections per group.
Scale bars 5 100 mm. Averaged values of epidermal thickness per mice are shown in the graphic at right.
C, Representative density plots of skin neutrophil (Ly6G1; top) and macrophage (CD641; right) populations
on CD451 live cells. Density values of cells are shown in the graphics. D, Histogram (upper) and individual
values (bottom) of LAT1 fluorescence in live keratinocytes. E, Density plots (left) and individual values of
frequencies (right) of Ki-671 (upper panels) and BrdU1 (lower panels) cells from live keratinocytes. F, Dot
plots of Vg41d41 (upper) and BrdU1d41 (bottom) cells from live CD272 gd T cells quantified in the lymph
nodes. G, Dot plots of the frequency of BrdU1 CD4 T cells in lymph nodes. Individual values of frequencies
(left) and total cell numbers (right) are shown in the graphs (Fig 2, F andG). A representative experiment of 2
is shown (n5 4-7 per group). Data are represented asmeans6 SEMs. ns, Not significant. ***P < .001, 1-way
ANOVA with the Bonferroni post hoc test (Fig 2, B-G).
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prevents psoriasis
To simultaneously study the function of LAT1 in adaptive and
innate lymphocytes, we crossed LAT1fl/fl mice17 with
RORgt-Cre1/2 mice29 and Rosa26-floxed stop tdTomato
mice.27 Characterization of LAT1DRgt mice revealed that specific
deletion of LAT1 in the skin occurs in cells that had expressed
and/or were expressing RORgt, including dermal gd T cells,
skin-resident type 3 innate lymphoid cells, and skin CD4 T cells
(see Fig E2, A, in this article’s Online Repository at
www.jacionline.org). Expression of Cre-recombinase was
detected in CD272 gd T cells within lymph nodes (see Fig E2,
B). These are mainly IL-17–secreting cells that also express
RORgt.30 Moreover, because RORgt is also expressed during
T-cell development at the immature double-positive stage in the
thymus,31 deletion of LAT1 can occur also in most TCRab
T-cell subsets (see Fig E2, B). Indeed, in vitro–activated CD4 T
cells from LAT1DRgt mice did not express LAT1 (see Fig E2,
C). Also, these cells were smaller and less complex (see Fig E2,
D) and displayed defective amino acid uptake (see Fig E2, E).
To ascertain whether deletion of LAT1 in RORgt1 cells could
affect skin lymphocyte populations at steady state, we analyzed
the distribution of different skin CD31 T-cell subsets. No
significant differences in the frequency or absolute numbers of
dermal CD4 and gd T cells, which were mostly Tm1, were
detected in LAT1DRgt and LAT1WT mice at steady state (see
Fig E2, F). Epidermal gd T cells (dendritic epidermal T cells),
which were identified by greater TCR expression, did not express
RORgt or Tm and were otherwise unaffected by LAT1 deletion in
the other subsets (see Fig E2, F).
Compared with LAT1WT mice, induction of psoriasis in
LAT1DRgt mice was clearly reduced, with a smaller area affected
and an almost complete absence of redness and squamous
appearance (Fig 3, A). Protection in LAT1DRgt mice was
confirmed by analyzing keratinocyte proliferation by means of
H&E and Ki-67 staining of skin sections, which was markedly
reduced compared with that in LAT1WT mice (Fig 3, B).
IMQ-treated LAT1DRgt mice also displayed decreased infiltration
of neutrophils and monocyte-derived inflammatory macrophages
compared with IMQ-treated LAT1WT mice (Fig 3, C).
Importantly, lower numbers of dermal CD4 and gd T-cell
populations were observed in the dorsal skin of IMQ-treated
LAT1DRgt mice compared with LAT1WT mice (Fig 3, D).
Analysis of draining lymphoid cells from IMQ-treated
LAT1WT mice showed that IL-17–producing CD272 gd T cells
express LAT1 in contrast to CD271 gd T cells, which do not
secrete IL-17 (see Fig E3, A, in this article’s Online Repository
at www.jacionline.org). LAT1DRgt mice showed a reduced
frequency of CD272 Tm1 gd T cells and lower Ki-67
expression than IMQ-treated LAT1WT mice (Fig 3, E).
Moreover, application of IMQ increased expression of LAT1
in dermal Vg41 and Vg42 gd T cells in LAT1WT mice
(Fig 3, F). Similarly, LAT1 expression was mainly increased
in CD272 Vg41d41 T cells detected in draining lymph nodes
after IMQ application (Fig 3, G). These results indicate that
deletion of LAT1 affected innate and adaptive lymphocyte
expansion induced by IMQ, suggesting its potential role as a
therapeutic target in skin inflammation. In addition, LAT1DRgt
mice showed less ear thickness, S100A8/9 expression, and
neutrophil and macrophage skin infiltration than LAT1WTmice (see Fig E3, B-D) in an alternative model of psoriasis
induced by intradermal injection of IL-23.Specific target deletion of LAT1 in CD4 T cells
attenuates psoriasis
Although gd T cells are essential to develop psoriasis in the
IMQ- and IL-23–induced models,8,10 this population is not
the most abundant in patients with psoriasis, in which most of
the IL-17–secreting cells are TCRab cells.32 To determine
whether specific deletion of LAT1 in CD4 T cells controls
psoriasis development induced by IMQ, we crossed LAT1fl/fl
mice with CD4-Cre1/2 mice.33 LAT1 deletion in CD4 T cells
was confirmed by using Western blotting and FC analysis (see
Fig E4, A, in this article’s Online Repository at www.jacionline.
org). In vitro–activated CD4 T cells from LAT1DCD4 mice showed
reduced amino acid uptake compared with LAT1WT CD4 T cells
(see Fig E4, B). Importantly, the specific inhibitor of LAT1,
JPH203, completely blocked amino acid uptake in CD4 T cells,
indicating the relevance of this specific essential amino acid
transporter in CD4 T cells.
On treatment with IMQ, LAT1DCD4 mice displayed a smaller
affected area and reduced redness and squamous appearance
compared with LAT1WT mice (Fig 4, A). Histologic
assessment revealed reduced epidermal thickness in LAT1DCD4
mice (Fig 4, B). Numbers of infiltrating neutrophils and CD4 T
cells, but not Ly6C1macrophages and gdT cells, were attenuated
in the skin of LAT1DCD4 mice (Fig 4, C and D).
Expression of LAT1 was increased in CD4 T cells after IMQ
application (Fig 4, E). Moreover, CD4 T-cell proliferation was
induced by IMQ treatment in the lymph nodes of LAT1WT but
not of LAT1DCD4 mice (Fig 4, F). As a control, we tested the
proliferation of lymph node CD272 gd T cells, which
remained unaffected when LAT1 was deleted in CD4 T cells
(see Fig E4, C). Transcriptional expression analysis of purified
CD4 (Fig 4, G) and gd (see Fig E4, D) T cells from the draining
lymph nodes of mice treated with IMQ indicated that deletion of
LAT1 in CD4 T cells specifically controls IL-17 mRNA levels in
CD4 T cells but not in gd T cells.
Transcriptional levels of IL-22 and IFN-g in CD4 andgdT cells
after IMQ application were comparable between both genotypes
(Fig 4, G, and see Fig E4, D). IL-10 expression was reduced
in CD4 T cells from LAT1DCD4 mice compared with LAT1WT
mice (Fig 4, G) but was similar in gd T cells (see Fig E4, D).
Expression of LAT1 mRNA levels was also increased by IMQ
in CD4 T cells from LAT1WT mice (Fig 4, G).
Further stimulation with IL-23 and IL-1b of CD4 T cells
purified from lymph nodes of IMQ-treated mice showed that
LAT1DCD4 mice displayed lower levels of IL-17 and IL-22
expression (Fig 4, H and I). These data indicate that LAT1
controls expansion of CD4 T cells, as well as their ability to
secrete IL-17 and IL-22 in response to IL-23 and IL-1b
stimulation. Moreover, naive CD4 T cells from LAT1DCD4 and
LAT1WT mice were differentiated in vitro toward the TH17
program by means of addition of IL-6 and TGF-b in combination
with IL-23 plus IL-1b. CD4 T cells from LAT1DCD4 mice
displayed lower numbers of IL-171 cells and secreted less
IL-17 and IL-22 than cells expressing LAT1 (see Fig E4, E).
Human CD4 T cells from healthy donors were also in vitro
differentiated toward TH17 with the same cytokine cocktail
FIG 3. Deletion of LAT1 in innate and adaptive T cells prevents IMQ-induced psoriasis. A, Representative
pictures of LAT1WT and LAT1DRgt mice after IMQ. B, H&E-stained (top) and Ki-67–stained (bottom) sections.
Scale bars 5 100 mm. Averaged values of epidermal thickness are shown (right). C, Skin neutrophils
(Ly6G1L6C1; upper) and resident (CD641Ly6C2) versus inflammatory macrophages (CD641Ly6C1; bottom)
were quantified. D, Dermal CD4 (bottom and right) and gd T cells (middle and left) and epidermal gd T cells
(upper and left) were analyzed. Absolute numbers of cells are shown (Fig 3, C and D, right). E, Dot plots of
Tm1 gd T cells from CD31 cells (upper), Tm1 CD272 cells (middle), and CD272 gd Ki-671 T cells (bottom)
from total gd T cells are shown. Frequency values are indicated (right). F and G, LAT1 expression in Vg41
(top) and Vg42 (bottom) dermal T cells (Fig 3, F) and lymph node Vd41 (top) and Vd42 (bottom) T cells
(Fig 3,G) in normal and IMQ-treatedmice. Data are represented asmeans6 SEMs. Results of 2 independent
experiments are represented as absolute numbers per square millimeter (Fig 3, C; n 5 4). Individual data
from one representative experiment of 2 were shown (Fig 3, D-F; n 5 4-5). ns, Not significant. *P < .05,
**P < .01, and ***P < .001, 1-way ANOVA (Fig 3, C) or 2-way ANOVA (Fig 3, E and F) with the Bonferroni
post hoc test and the 2-tailed Mann-Whitney test (Fig 3, D).
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FIG 4. LAT1 expression in CD4 T cells contributes to development of IMQ-induced psoriasis.
A, Representative pictures of IMQ-treated LAT1WT and LAT1DCD4 mice. B, H&E-stained (top) and
Ki-67–stained (bottom) sections. Scale bars 5 100 mm. Averaged values of epidermal thickness are shown
(right). C, Skin neutrophil (Ly6G1; top) and macrophage (CD641; right) quantification. D, Dermal CD4
(right and bottom) and gd (left and middle) T cells and epidermal gd T cells (left and upper) were analyzed.
Total numbers (left) and Ki-671 dermal CD4 and gdT cells are shown (right).E, LAT1 expression in CD4 T cells
in lymph nodes. F, Frequencies (left) and absolute numbers (right) of CD41Ki-671 cells in lymph nodes.
G, Transcriptional expression in CD4 T cells after IMQ. H and I, Cytokines level (ELISA). I, Dot plots and
frequencies of IL-171 (upper) and IL-221 (lower) CD4 T cells obtained from IMQ-treated mice and stimulated
with IL-23 plus IL-1b and PMA/ionomycin. A pool of 2 independent experiments (Fig 4, C, D, F, and G)
or data from one of 2 experiments (Fig 4, E, H, and I; n 5 4-6) are shown. Data are shown as
means 6 SEMs. ns, Not significant. *P < .05, **P < .01, and ***P < .001, 2-tailed unpaired Student t test
(Fig 4, C-E), 1-way ANOVA (Fig 4, F andG), or 2-way ANOVA (Fig 4,H and I) with the Bonferroni post hoc test.
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FIG 5. The inhibitor of LAT1, JPH203, prevents IMQ-induced skin inflammation. A, Representative pictures
from mice treated with DMSO or JPH203 and topical application of IMQ. B, Dot plots identifying
macrophages (CD641CD11b1; top) and neutrophils (Ly6G1Ly6C1; bottom) in CD451 and CD451CD642
populations in the dorsal skin, respectively. Density values of macrophages and neutrophils are shown
(right). C, Representative H&E-stained (top) and Ly6G-stained (bottom) skin sections. Scale bars 5 100
mm. Averaged values of epidermal thickness per mouse are shown in the graphic at right. D, Relative
fold induction of indicated genes induced in the skin by IMQ. E, Representative density plots for CD272
and CD271 TCRgd T cells in the CD31 gated population (upper) and frequencies of Vd41Ki-671 cells on gated
CD272 gd T cells (bottom) in skin-draining lymph nodes. Absolute numbers or frequencies detected in
cellular lymph node suspensions are shown per group (right). A pool of 2 independent experiments (Fig
5, B and E) or data from one of 2 individual experiments (Fig 5, D) are shown (n 5 4-5). Data are shown
as means 6 SEMs. ns, Not significant. *P < .05 and **P < .01, 1-way ANOVA with the Bonferroni post
hoc test (Fig 5, B, D, and E).
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FIG 6. LAT1 acts as an upstream regulator of mTOR in the control of IMQ-induced psoriasis.
A, Representative pictures of mice after 4 days of IMQ and treated with DMSO, rapamycin (Rapa), or
JPH203 plus rapamycin. B, Representative H&E-stained skin sections per group. Scale bars 5 100 mm.
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CIBRIAN ET AL 209(see Fig E4, F). After 12 days in culture, stimulation with phorbol
12-myristate 13-acetate (PMA) and ionomycin confirmed that
LAT1 inhibition controls secretion of IL-17 and IFN-g in human
CD4T cells. These results indicate that LAT1 expression is neces-
sary for human and mouse CD4 TH1 and TH17 polarization.Pharmacologic inhibition of LAT1 prevents IMQ-
induced psoriasis in mice
Mice were randomly treated with dimethyl sulfoxide (DMSO;
vehicle) or LAT1 inhibitor (JPH203) to ascertain whether
pharmacologic inhibition of LAT1 can affect IMQ-induced
psoriasis severity. Inhibition of LAT1 during IMQ application
caused a marked reduction of the appearance of psoriasis
hallmarks, such as redness, epidermal thickening, and neutrophil
infiltration (Fig 5, A-C).
To confirm the beneficial effect of JPH203 against psoriasis, we
evaluated transcriptional levels of several proinflammatory
mediators in the skin (Fig 5, D) and draining lymph nodes (see
Fig E5, A, in this article’s Online Repository at www.jacionline.
org). JPH203 treatment prevented the increase in IL-1b, IL-
17A, IL-22, S100A8, and S100A9 levels induced by IMQ in the
skin (Fig 5, D). Interestingly, reduced transcriptional expression
of CCR6 was also detected in the skin of JPH203-treated mice
compared with that in DMSO-treated mice, which is consistent
with a reduction in skin infiltration by IL-17–releasing cells.34
In contrast, we found no difference in IL-23 and IFN-g levels
(Fig 5,D). These experiments also revealed reduced transcription
of IL-17 and IL-22 in skin-draining lymph nodes from JPH203-
treated mice (see Fig E5, A). However, transcriptional levels of
IL-10, IFN-g, CCL5, and CCL20 were comparable in both the
JPH203- and DMSO-treated groups. Likewise, increased tran-
scriptional levels of the LAT1 gene (Slc7a5) but not the CD98
gene (Slc3a2) were found in the lymph nodes of IMQ-treated
mice supplemented with JPH203 or DMSO compared with the
control group (see Fig E5, A).
Inhibition of LAT1-mediated amino acid transport prevented
IMQ-induced expansion of gd T cells in skin-draining lymph
nodes, which mostly express g4 and d4 chains (Fig 5, E).
A significant reduction in numbers of CD272 gd T cells was
detected in mice treated with JPH203 compared with the
DMSO group, whereas the population of CD271 gd T cells
remained unaffected (Fig 5, E). CD272 g41d41 T cells displayed
high levels of Ki-67, indicating that they actively proliferate in the
DMSO-treated group, whereas their proliferation was
significantly reduced in mice treated with JPH203. These data
indicate that LAT1 inhibition controls CD272 gd T-cell
proliferation (Fig 5, E).
Moreover, the skin of mice treated with JPH203 contained
fewer infiltratingVg41d41T cells than the skin of DMSO-treated
mice (see Fig E5, B). Skin-infiltrating Vg41d41 T cells were
mostly positive for Ki-67 in DMSO-treated mice, indicating theirC,Dot plots of Vg41d41 (upper) and density plots of Ki-6
in the lymph nodes. D, Dot plots of frequencies of K
Individual values per mouse of frequencies (Fig 6, C) a
Purified gd T cells (left), lymph node cells depleted of g
of IMQ-treated mice of indicated genotypes were in vi
incubated with indicated inhibitors. Individual values pe
by means of ELISA are shown. A pool of 2 independe
representative experiment of 2 (Fig 6, E) are shown (n
significant. *P < .05, **P < .01, and ***P < .001, 1-way Aproliferative activity. Also, JPH203 significantly reduced the fre-
quency of Ki-671Vg41d41 T cells in the skin (see Fig E5, B). In
addition to its effect on gd T cells, JPH203 also controlled the
expansion of CD4 T cells (data not shown).
In summary, systemic administration of the LAT1 inhibitor
JPH203 attenuates the skin response to IMQ by limiting the
expression of most proinflammatory mediators as well, as the
proliferation of CD4 and gd T cells.
Human gd T cells can be activated and expanded by
phosphorylated antigens, such as zoledronate.35 After 10 days,
the presence of Ki-671 gd T cells is greater than 85% (data not
shown), but cotreatment with JPH203 significantly prevented
their expansion (see Fig E5, C). Western blot analysis of human
gd T cells confirmed expression of the LAT1-CD98 complex
(see Fig E5, C).The LAT1/mTOR axis controls inflammatory
responses in the IMQ-psoriasis model
To evaluate the role of mTOR activation in the control of CD4
and Vg41d41 T-cell expansion in mice with LAT1 deletion or in-
hibition, we assessed the effect of the mTOR inhibitor rapamycin
alone or in combination with JPH203 (JPH203 plus rapamycin)
during IMQ challenge. Mice treated with rapamycin or JPH203
plus rapamycin displayed reduced skin inflammation induced
by IMQ (Fig 6,A) and reduced epidermal thickness (Fig 6,B). Ra-
pamycin and JPH203 plus rapamycin caused a similar reduction
in the frequency of Vg41d41 T cells detected in the draining
lymph nodes (Fig 6,C). The fraction of Vg41d41T cells express-
ing Ki-67 was reduced by rapamycin, but no additional inhibitory
effect was caused by JPH203 (Fig 6, C). In addition, expansion of
CD4 T cells induced by IMQ was prevented by rapamycin or
JPH203 plus rapamycin (Fig 6, D). Overall, no additional effect
was observed by treatment with JPH203 in mice in which we
had already inhibited mTOR signaling in inflammatory cells,
indicating that LAT1 might be upstream of the mTOR pathway.
We next assessed the role of the LAT1/mTOR axis in the
control of IL-17 and IL-22 secretion after stimulation with IL-23
and IL-1b. Lymph node cells from LAT1DRgt and LAT1WT mice
treated with IMQ were used to obtain separate fractions of puri-
fied gd T cells and the remaining lymph node cells. Both frac-
tions, as well as total ear cell suspensions, were in vitro
stimulated with IL-23 plus IL-1b with or without JPH203 alone
or together with rapamycin (Fig 6, E). Cells derived from IMQ-
treated LAT1DRgt mice barely responded to IL-23 plus IL-1b
stimulation (ie, they did not secrete IL-17 and IL-22), and the
inhibitory effects observed with JPH203 and JPH203 plus rapa-
mycin were significant only in cells expressing LAT1. In addition,
no significant differences were detected between cells treated
with JPH203 alone and those treated with JPH203 plus rapamycin
(Fig 6, E), further indicating that LAT1 acts upstream of mTOR to
control IL-17–related cytokine release.71d41 (bottom) from live CD272 gd T cells quantified
i-671 cells from CD4 T cells in the lymph nodes.
nd total cell counts (Fig 6, D) are shown at right. E,
d T cells (middle), and skin cell suspensions (right)
tro stimulated (24 hours) with IL-23 plus IL-1b and
r mouse of cytokine levels detected in supernatants
nt experiments (Fig 6, C and D) or data from one
5 4-6). Data are shown as means 6 SEMs. ns, Not
NOVA with the Bonferroni post hoc test (Fig 6, C-E).
FIG 7. IL-23 and IL-1b upregulate LAT1 expression and induce mTOR activation in IL-17–secreting cells.
A and B, Representative histograms (upper) and individual values (bottom) of LAT1 fluorescence in
Vg41 cells from lymph node cells of IMQ-treated mice (Fig 7, A) and in vitro–skewed TH17 cells from WT
mice (Fig 7, B) after IL-23 plus IL-1b stimulation. C, Peripheral CD4 T cells from healthy donors and patients
with psoriasis were in vitro stimulated (48 hours) with IL-23 plus IL-1b. Expression of LAT1 and the
LAT1-CD98 heterodimeric complex determined by using Western blotting are shown. D, Total lymph
node gd T cells from IMQ-treated WT mice were stimulated (24 hours) with IL-23, IL-1b, or both. Dot plots
(left) and frequencies (right) of P-S6 expression in g41 (upper) and g42 (bottom) cells are shown.
E, Histograms (upper) and values of fluorescence intensity for P-S6 expression (bottom) in the total fraction
of CD272g41 T cells stimulated as in Fig 7, D. A representative experiment of 2 individual replicates is
shown (at least n 5 5 [Fig 7, A, B, D, and E] and n 5 2 [Fig 7, C] samples per group). Data are represented
as means 6 SEMs. ns, Not significant. *P < .05 and ***P < .001, 1-way ANOVA (Fig 7, A, D, and E) with
the Bonferroni post hoc test and the 2-tailed paired Student t test (Fig 7, B).
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AKT/mTOR pathway in IL-17–secreting cells
We further explored the mechanism through which LAT1
controls expansion of immune cells in psoriasis. A previous study
proposed that AHR controls gd T-cell proliferation in response to
IMQ.36 To address this, we inhibited LAT1 in AHR1/2 and
AHR2/2 mice. JPH203 treatment dampened CD272 gd andspecifically Vg41d41 T-cell expansion in IMQ-treated AHR1/2
and AHR2/2 mice groups (see Fig E6, A, in this article’s Online
Repository at www.jacionline.org), indicating that the effect of
LAT1 inhibition on gd T-cell proliferation is largely independent
of AHR expression. Moreover, JPH203 decreased the frequency
and number of IL-17–secreting gd T cells in both genotypes after
IMQ challenge (see Fig E6, B).
FIG 8. LAT1 is required to activate the PI3K/AKT/mTOR pathway induced by IL-23 and IL-1b to promote
proliferation of IL-17–releasing cells. A, Lymph node cells from IMQ-treated mice were stimulated in vitro
(48 hours) with the indicated cytokines and inhibitors. Dot plots (left) and individual values (right) of
gd T-cell frequencies from CD31 cells are shown. B, Density plots (left) and frequencies (right) of BrdU1
and P-S61Vg41 cells obtained and stimulated as in Fig 7, A. C, Representative histogram of P-S6 expression
(left) and individual values of P-S6 fluorescence (right) in Vg41 cells is shown. A representative experiment
of 2 individual replicates is shown (at least n 5 5). Data are shown as means 6 SEMs. ns, Not significant.
*P < .05 and ***P < .001, 2-way ANOVA with the Bonferroni post hoc test.
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psoriasis, we assessed the effect of the proinflammatory cytokines
IL-23 and IL-1b. Both cytokines play crucial roles in TH17 devel-
opment37 and promote extrathymic commitment of IL-171 gd T
cells in the IMQ model.12 LAT1 expression was significantlyincreased by IL-23 plus IL-1b stimulation in Vg41 T cells
from the lymph nodes of mice treated with IMQ (Fig 7, A). Stim-
ulation with IL-23 and IL-1b also increased LAT1 expression of
CD41IL-171 T cells differentiated in vitro (Fig 7, B). Moreover,
peripheral CD4 T cells from patients with psoriasis expressed
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plus IL-1b compared with cells from healthy donors (Fig 7, C).
These results suggested that LAT1 is essential for the expansion
of IL-17–secreting T lymphocytes induced by IL-23 and IL-1b.
IL-23 and IL-1b also induce activation of the mTOR pathway,
as assessed by an increase in P-S6 detection, in gd T cells (Fig 7,
D and E). Remarkably, the combination of IL-23 plus IL-1b po-
tentiates the effect of each cytokine alone on P-S6 activation in
both g41 and g42 T cells (Fig 7, D and E).
Stimulation with IL-23 plus IL-1b induced expansion of Vg41
cells but only when LAT1 was expressed (Fig 8, A). However,
expansion of Vg41 T cells from LAT1WT mice is reduced by
addition of either mTOR or LAT1 inhibitors. These inhibitors
had no effect on cells from LAT1DRgt mice (Fig 8, A). Finally,
the combination of mTOR and LAT1 inhibitors had no additive
effect, further confirming that LAT1 and mTOR are likely part
of the same signaling pathway in these cells. The effects of
IL-23 plus IL-1b stimulation in BrdU incorporation and S6 phos-
phorylation in Vg41T cells were completely blocked by PI3K in-
hibitor (Ly294002) or by amino acid depletion (Fig 8, B). Cells
from LAT1DRgt mice did not display mTOR activation or prolif-
eration under any of the conditions assayed (Fig 8, C). These
data indicate that IL-23 and IL-1b trigger LAT1 expression in
Vg41 T cells and TH17 cells, which promotes PI3K/AKT-
induced mTOR signaling to control their expansion and IL-17
secretion.DISCUSSION
The pathogenesis of psoriasis requires complex mechanisms
that involve the interplay between keratinocytes and inflamma-
tory cells.1 Genetic studies aimed at identifying new genetic path-
ways associated with psoriasis risk demonstrated that alterations
in metabolic pathways, such as those involved in transporting
inorganic ions and amino acids, positively correlate with
increased psoriasis risk.38 Increased transcriptional levels of
Slc7a5 were detected in skin samples of patients with psoriasis.22
The present study represents the first description of the
increased expression of LAT1 protein in psoriatic lesions in
keratinocytes and infiltrating lymphocytes. Pharmacologic
inhibition of LAT1 effectively blocks skin inflammation induced
in mice by means of IMQ application. The anti-inflammatory
effects of the inhibitor can be recapitulated by genetic deletion
of LAT1 in lymphocytes, including RORgt-expressing cells,
such as gd T cells and CD4 T cells.
The mTOR pathway is hyperactivated in keratinocytes from
patients with psoriasis.39 Its aberrant induction is mediated by
proinflammatory cytokines, such as IL-1b, IL-17A, and TNF-a,
increasing proliferation and reducing expression of differentia-
tion markers.40 Our results indicate that LAT1 expression in ker-
atinocytes is not essential for control of keratinocyte proliferation,
indicating a functional compensation with alternative amino acid
transporters, such as LAT2 or LAT3, which are also expressed in
the epidermal layer in patients with psoriasis.
A major feature of the IMQ model is expansion of
CD272g41d41 T cells in draining lymph nodes that produce
IL-17.12,28,41 A similar expansion of this population is observed
in a mouse experimental autoimmune encephalomyelitis
model.42 Our results demonstrate that IL-171g41d41 T-cell
expansion after skin sensitization with IMQ is blocked by target-
ing LAT1 pharmacologically or genetically. Importantly, LAT1inhibition also blocks expansion of human gd T cells. Further ex-
periments will address whether LAT1 deletion controls g41 T-
cell expansion in patients with other IL-17–mediated diseases,
such as autoimmune encephalomyelitis.
LAT1 inhibition controls the proliferation of Vg41d41 T cells,
even in the absence of AHR. However, LAT1 inhibition in the
presence of the canonical mTOR inhibitor rapamycin had no ad-
ditive effect. Inhibition of mTOR by targeting LAT1 could be an
alternative approach to specifically target immune cells stimu-
lated by IL-23 and IL-1b in patients with inflammatory diseases.
LAT1 deletion in dermal gd T cells also effectively controls IL-
23–induced skin inflammation. Nevertheless, the main disadvan-
tage of IMQ- and IL-23–induced murine models of psoriasis is
their dependence on gd T cells.8,10 Although the increased fre-
quency of gd T cells has been observed also in human psoriatic
lesions,2 their relevance in the onset or recurrence of disease is
not clearly established.43,44 Indeed, human psoriatic lesions
show a greater frequency of IL-17–releasing TCRab1 T cells
than gd T cells.32 Our data demonstrate that LAT1 deletion in
CD4 T cells dampens IMQ-induced skin inflammation. More-
over, LAT1 inhibition successfully impairs the TH17 differentia-
tion program in human CD4 T cells. Because the LAT1 inhibitor
JPH203 is currently in clinical trials,21 we propose that blocking
LAT1-mediated amino acid transporter merits consideration as a
novel immunosuppressive strategy to control the expansion of
innate and adaptive T cells in the reactive state in patients with in-
flammatory diseases.
Whether mTOR activation is required for TH17 cell expansion
has been studied extensively45; however, the role of TH17 driver
cytokines, such as IL-23 and IL-1b, in mTOR activation had
not been fully characterized. TH17 cell development required
TCR-mediated activation, which triggers the PI3K/AKT/mTOR
signaling axis. LAT1 expression is induced after TCR
engagement and is essential to properly activate ab T cells.17
LAT1 expression after TCR activation requires nuclear
factor k-light-chain-enhancer of activated B cells (NF-kB) and
activator protein 1 activation.46 The data herein clearly show
that IL-23 and IL-1b stimulation also regulates LAT1 expression
in TH17 cells, as well as in gd T cells, which do not receive TCR
input.
IL-23–induced Janus kinase 2 activation triggers the
PI3K/AKTand NF-kB pathways.47 IL-1b stimulation can induce
NF-kb activation through myeloid differentiation response gene–
88,48 which is also essential for mTOR activation in TH17 cells.
49
Moreover, IL-1R signaling induced PI3K/AKT phosphorylation
and mTOR activation to promote differentiation of pathogenic
TH17 cells.
50 Our data indicate that inhibition of PI3K/AKT or
amino acid depletion abrogated mTOR activation induced by
IL-23 and IL-1b in gd T cells. Importantly, PI3K/AKT signaling
is important for expansion of IL-17–secreting gd T cells.51,52 Our
data suggest that IL-23 and IL-1b induce LAT1 expression as a
positive feedback loop to drive activation of that PI3K/AKT/
mTOR pathway, which is essential for increased survival and
expansion of IL-17–releasing cells.
LAT1 inhibition decreased transcriptional levels of IL-1b in
the skin. This effect is potentially related to blockade of amino
acid uptake in skin macrophages, which is also involved in IL-1b
secretion.53 This additional anti-inflammatory effect of JPH203
might contribute to prevention of psoriasis. However, genetic
deletion of LAT1 in gd and CD4 T cells was sufficient to control
disease development.
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CIBRIAN ET AL 213This work provides the first evidence that murine psoriasis
models can be preciselymodulated by targeting inflammatory cell
metabolism. Our data postulate that the LAT1 inhibitor JPH203,
which has already been tested in patients with cancer for
biosafety,54 could be an alternative to control chronic skin
inflammation.
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Key messages
d LAT1 (SLC7A5) expression is increased in patients with
psoriasis in both keratinocytes and dermal infiltrating
lymphocytes, and its expression is upregulated by IL-23
and IL-1b.
d LAT1 inhibition does not affect keratinocyte proliferation
but impairs expansion of IL-17–secreting gd and
CD4 T cells.
d LAT1 controls IL-23 plus IL-1b–induced PI3K/AKT/
mTOR signaling in IL-17–secreting gd and CD4 T cells
to guarantee their expansion and cytokine secretion.REFERENCES
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METHODS
Chemical reagents
The LAT1-specific inhibitor JPH203, (S)-2-amino-3-(4-((5-amino-2-
phenylbenzo [d] oxazol-7-yl) methoxy)-3,5-dichlorophenyl) propanoic acid,
was purchased fromMedKoo Biosciences (Morrisville, NC). All other reagents
were purchased from Sigma (St Louis, Mo), unless otherwise indicated.
Mice
Mice were bred and maintained in the specific pathogen–free animal
facilities of Centro Nacional de Investigaciones Cardiovasculares (Madrid,
Spain). All animal experiments were performed in accordance with protocols
approved by the institutional animal care committee and were approved by
local and European ethics committees. For all experiments, we used
littermates derived from crossing Cre-negative Slc7a5fl/fl tomatofl/wt female
mice with Cre-positive Slc7a5fl/wt tomatofl/wt male mice. LAT1WT mice are
Cre1/2Slc7a5fl/wtTomatofl/wt mice, and LAT1D mice are Cre1/2Slc7a5fl/flTo-
mato
fl/wt
mice. K5-CreERT2 mice were kindly provided by Erwin Wagner
(Medical University, Vienna, Austria). Mice (4 weeks) were fed with a 400-
ppm tamoxifen diet (TD55125; Envigo, Indianapolis, Ind) for induction of
Cre protein in the skin. AHR2/2micewere kindly provided by Pedro Salguero
(Universidad de Extremadura, Badajoz, Spain). AHR2/2 mice and their con-
trol littermate AHR1/2micewere obtained by breeding heterozygous parents.
Forkhead box P3–mRFP reporter mice backcrossed with IL-17–green fluores-
cent protein reporter mice were kindly provided by Richard A. Flavell (Yale
University, NewHaven, Conn) and used as normal (WT)mice for experiments
with either JPH203 or rapamycin inhibitors. All mouse strains used are on the
C57BL/6 background. Experiments were conducted with male mice (8-12
weeks) kept on a regular 12-hour light/dark cycle (7 AM-7 PM light period),
with food and water available ad libitum.
Human subjects
Patients with moderate-to-severe psoriasis whowere recruited for the study
had a Psoriasis Area and Severity Index of 8.0 or greater and washout periods
of at least 14 days for topical corticosteroids and any systemic therapy. Skin
punch biopsy specimens (3 mm) were obtained from patients with lesion
plaque–type psoriasis and healthy volunteers. Blood samples (10 mL) were
also collected from patients with psoriasis and healthy volunteers. The study
was approved by the Hospital Universitario de La Princesa ethics committee,
and all participants provided written informed consent.
Psoriasis model induction and treatment
Induction of local psoriasis-like inflammation on ear skin was done through
daily topical administration of 10 mg of IMQ cream (5%) in each ear for 4 or 5
days. For systemic psoriasis induction, mice were mostly treated daily on
shaved and depilated back skin with 50 mg of IMQ cream for 4 or 5 days.
Exceptionally, LAT1DCD4 mice received 20 mg of IMQ daily on back skin for
8 days. When indicated, mice received daily doses of JPH203 (50 mg/kg of
body weight) and rapamycin (5 mg/kg of body weight) dissolved in DMSO
(through the intraperitoneal route) during the course of IMQ treatment.
Mice without IMQ or treatment application are always included as a control
group. The IL-23 model of psoriasis was conducted, as previously descri-
bed.E1 At least 10 intradermal injections of recombinant mouse IL-23 (500
ng in 20mL of PBS; eBioscience, SanDiego, Calif) were performed permouse
on alternate days. When indicated, mice received an injection of 50 mL (250
mg) of Brefeldin A (Sigma) dissolved in ethanol (5 mg/mL) and administered
intraperitoneally 12 hours before death. For in vivo BrdU labeling of cells, 1
mg of BrdU dissolved in 100mL of PBSwas injected intraperitoneally 3 hours
before mice were killed.
Skin analysis and staining
For histologic analysis, paraformaldehyde-fixed, paraffin-embedded dorsal
skin sections were prepared and stained with H&E. At least 3 skin sections
(3-5 mm) 300 mm apart from each other were analyzed per mouse. For
quantification of epidermal thickness, at least 10 measurements, randomly
performed between all sections, were averaged per mouse. For
immunohistochemical staining, skin sections were deparaffinized, boiled in
the suggested antigen retrieval solution, and incubated with the primary
antibodies indicated in Table E1. Slides were developed with
diaminobenzidene substrate (K3468; Dako, Glostrup, Denmark) and
then counterstained with Mayer hematoxylin. For immunofluorescence of
LAT1 in mice, fresh skin fragments were embedded in OCT compound.
IL-17–green fluorescent protein was detectable in unfixed skin sections
without staining.
Human skin sections were deparaffinized, boiled in the suggested antigen
retrieval solution, blocked with BSA solution (2%), and incubated with the
primary antibodies indicated in Table E1 for 18 hours at 48C. The secondary
antibodies used were the EnVision FLEX system for immunohistochemistry
detection of LAT1/LAT2 (Dako) and Alexa Fluor 647–labeled chicken anti-
rabbit for LAT1/LAT2 and LAT3 immunofluorescences. Nuclei were counter-
stained with 49-6-diamidino-2-phenylindole dihydrochloride. Pictures were
taken with a Zeiss LSM confocal microscope (Zeiss, Oberkochen, Germany)
and analyzed with LSM image browser software.
Lymphocytes and skin cell preparations for FC
Tissues were dissected and grated through a nylon mesh (70-mm; BD
Biosciences, San Jose, Calif) to obtain single-cell suspensions from
peripheral lymph nodes. RBC lysis was performed with BD Pharm Lyse
Buffer (BD Biosciences). Ears were split into dorsal and ventral halves, and
dorsal skin was cut into small pieces. Tissues were digested for 30 minutes
at 378C in RPMI containing penicillin-streptomycin, HEPES buffer,
83 mg/mL Liberase (Roche Applied Science, Mannheim, Germany),
100 mg/mL DNAse I (Sigma), and 0.5 mg/mL Collagenase IV (Sigma)
under constant stirring. Digestion enzymes were quenched by addition of
5 mmol/L EDTA and 0.5% BSA. Undigested tissue was homogenously
disaggregated with 7-mm stainless steel beads (Life Technologies, Grand
Island, NY) in a TissueLyser LT (Qiagen, Hilden, Germany), one 3-minute
cycle (20 osc/sec). Isolated skin cells were flowed through a 70-mm nylon
filter (BD Biosciences). For analysis of keratinocytes, dorsal skin frommice
treated or not with IMQ was incubated with 4 U/mL Dispase II (Roche)
in MEM medium by 24 hours at 48C. True count beads (BD Biosciences)
were added to cell suspensions to quantify the total number of cells in
further FC.
FC
Single-cell suspensions were incubated with Fc-blocking antibodies and
subsequently stained with 1:200 dilutions of the appropriated surface marker
antibodies detailed in Table E1. The staining panels always included dead cell
staining with Fixable Yellow Viability Dye (Molecular Probes, Eugene, Ore).
BrdU detection was performed according to the manufacturer’s protocol (BD
PharMingen). P-S6 (Ser235/236) (pS6) and Ki-67 staining were conducted
with the FOXP3 Transcription Factor Staining Buffer Set (eBioscience) and
with directed labeled antibodies against Ki-67 (B56; BD Biosciences) and
pS6 (D57.2.2E; Cell Signaling, Danvers, Mass). For LAT1 and LAT2
detection, cells were fixed and permeabilized with Cytofix/Cytoperm Kit
(BD Biosciences), and Alexa Fluor 647–labeled chicken anti-rabbit was
used as a secondary antibody. A customized rabbit anti-mouse LAT2 (kindly
provided by Dr Manuel Palacın, IRB, Barcelona, Spain) was used. Further
description of antibodies is included in Table E1.
After staining, cells were washed and analyzed with FACSCanto or
LSRFortessa (BD Biosciences). Data were further analyzed with FlowJo10
software (TreeStar, Ashland, Ore).
In vitro cultures and cytokine detection
Mouse cells were cultured in RPMI or Iscove modified Dulbecco medium
supplemented with FCS (5%), 25 mmol/L HEPES, antibiotics, sodium
pyruvate, and b-mercaptoethanol. When indicated, cells were incubated in
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RPMI 1640 mediumwithout amino acids and supplemented with normal FCS
(5%; United States Biological, Salem,Mass). Naive CD4 T cells were purified
from lymph nodes by using commercial kits (STEMCELL Technologies,
Vancouver, British Columbia, Canada).
Naive CD4T cells were seeded (13 106 cells/mL) in a 24-well plate coated
with 5 mg/mL anti-CD3 (145 2C11; Tonbo Biosciences, San Diego, Calif) for
48 hours to test LAT1 expression and amino acid uptake experiments. For
in vitro differentiation studies, naive CD4 T cells were seeded (1 3 106
cells/mL) in supplemented Iscove modified Dulbecco medium in 24-well
plates coated with 5 mg/mL anti-CD3 (145 2C11) and 1 mg/mL anti-CD28
(37.51) antibodies (Tonbo Biosciences) and steered toward the TH17 lineage
with IL-6 (50 ng/mL), IL-23 (10 ng/mL), IL-1b (10 ng/mL), and TGF-b (1
ng/mL) for 4 days. When indicated, the TH17 cells were cultured with IL-6
and TGF-b for 4 days at concentrations indicated previously, and stimulation
with IL-23 and IL-1b was tested only by 24 hours.
Total CD4 T cells purified from LAT1WT and LAT1DCD4 mice after IMQ
application were incubated by 18 to 24 hours with IL-23 and IL-1b cytokines
(10 ng/mL each) to stimulate secretion of cytokines and P-S6 induction or 48
hours to assess proliferation. Similarly, cell suspensions from lymph nodes of
LAT1WTand LAT1DRgt mice after IMQ application were split into 2 fractions:
one was subjected to gd T-cell depletion using anti-TCRgd (clone GL3), and
the other was used to purify gd T cells with the EasySep Mouse Selection Kit
(STEMCELL Technologies). The resulting fractions (purified gd and
gd depleted) were in vitro stimulated by 18 to 24 hours with IL-23 and IL-
1b to assess cytokine release by means of ELISA. Ear cell suspensions after
IMQ application were also in vitro stimulated with IL-23 and IL-1b to assess
cytokine release. Supernatants were collected, and IL-17 and IL-22 levels
were assessed by using mouse ELISA Ready-SET-Go Kits (Fisher Scientific,
Waltham, Mass). CD4 T cells were further stimulated with PMA (50 ng/mL;
Sigma), ionomycin (1 mg/mL; Sigma-Aldrich), and brefeldin A (GolgiStop, 1
mg/mL; BD Biosciences) at 378C in a 10% CO2 atmosphere for 4 hours. After
staining of surface markers, cells were fixed and permeabilized (Cytofix/Cy-
toperm and Perm/Wash Buffer; BD Biosciences), followed by staining with
mAbs to mouse IL-17A and IL-22 (eBioscience). True count beads (BD Bio-
sciences) were added to in vitro cultures to quantify the total number of
expanded gd T cells. Rapamycin (1 mmol/L), LY294002 (10 mmol/L), and
JPH203 (10 mmol/L) inhibitors were added to the cultures when indicated.
When indicated, BrdU at a final concentration of 5mmol/Lwas added to assess
proliferation according to the instructions of the BrdU FlowKits (BDLife Sci-
ence-Bioscience).
PBMCs from healthy donors were obtained, and CD4 T cells were isolated
by using the EasySep Human CD4 T Cell Isolation Kit (STEMCELL
Technologies). For TH17 differentiation, isolated CD4 T cells were cultured
for 12 days in RPMI 1640 medium supplemented with FCS (5%), 25 mmol/
L HEPES, antibiotics, and sodium pyruvate with anti-CD3 (5 mg/mL; catalog
no. 300314, RRID:AB314050; BioLegend) plus anti-CD28 mAbs (2 mg/mL;
catalog no. 555725; BD). The following combination of cytokines and block-
ing antibodies was appropriate for TH17 polarization: rhIL-6 and IL-1b (10
ng/mL), rhIL-23 (20 ng/mL), rhTGF-b1 (2 ng/mL), anti–IFN-g (10 mg/
mL), and anti–IL-4 (10 mg/mL; all cytokines from R&D Systems, Minneap-
olis, Minn) were added each 48 hours. JPH203 at 10 mmol/L or DMSO was
also added to the culture on alternate days. At day 12, cells were further stim-
ulated by 4 hours with PMA (50 ng/mL; Sigma) and ionomycin (1 mg/mL;
Sigma-Aldrich) in the presence of brefeldin A (GolgiStop, 1 mg/mL; BD Bio-
sciences). Fixed and permeabilized cells (Cytofix/Cytoperm and Perm/Wash
Buffer; BD Biosciences) were stained with anti–IL-17 (BL168) and anti–
IFN-g (B27) antibodies (BioLegend) and analyzed in a FACScanto cytometer.
For expansion of human gd T cells, total human PBMCs (106 cells/mL)
from heathy donors (buffy coats) were stimulated in a 24-well plate in culture
medium EX-VIVO 15 (Lonza, Bornem, Belgium) and expanded with zole-
dronic acid (5 mmol/L), as previously reported.E2 At day 2, IL-2 (100 U/
mL) and JPH203 inhibitor (10 mmol/L) were added and then replaced every
48 hours. At day 10, the number of Ki-671CD272 gd T cells was analyzed
in a FACSCanto cytometer. LAT1 expression associated with CD98 was
also confirmed in expanded (10 days) human gd T cells by means of Western
blotting.
RNA extraction and quantitative PCR analysis
Tissue total RNA was isolated with TRI Reagent (Sigma) or the Qiagen
RNeasy Kit (Qiagen). Residual DNA contamination was removed with the
Turbo DNA-free Kit (Ambion, Thermo Fisher, Waltham, Mass). Total RNA
(200-1000 ng) was reverse transcribed to cDNAwith a Reverse Transcription
Kit (Applied Biosystems, Foster City, Calif). Quantitative PCR was then
performed in an AB7900_384 (Applied Biosystems) by using SYBR Green
(Applied Biosystems) as a reporter. Gene-specific primers used are listed in
Table E2. Expression of each gene of interest was normalized to at least 2
housekeeping genes: b-actin (ACTB) and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). Data are presented as averaged relative fold differences
calculated by using the 22DDCt method with average values of healthy mice as
a reference.
Western blotting
CD4 T cells from LAT1DRgt and LAT1DCD4 mouse cell lines were cultured
(13 106 cells/mL) in RPMI medium for 24 hours in the presence of anti-CD3
(5mg/mL). After lysis with RIPA buffer supplementedwith protease and phos-
phatase inhibitor cocktails (Roche), lysates were separated by using SDS-
PAGE and immunoblotted with anti-LAT1 antiserum (kindly provided by
Dr P. Taylor, Dundee, United Kingdom).E3 The loading control was carried
out with a rabbit anti-mouse SMC protein 1A antibody (A300-055A; Bethyl
Laboratories, Montgomery, Tex).
gd T cells from PBMCs of patients with psoriasis were purified with the
EasySep Human Gamma Delta T Cell Isolation Kit (STEMCELL
Technologies) after 7-10 days in culture with zoledronate. CD4 T cells
purified from PBMCs of patients with psoriasis or healthy volunteers were
stimulated with anti-CD3 (2 mg/mL), anti-CD28 (1 mg/mL), IL-23 (20 ng/
mL), and IL-1b (20 ng/mL) for 48 hours. Lysates of human gd T cells and
CD4 T cells were done with RIPA buffer, separated by using SDS-PAGE,
and immunoblotted with rabbit anti-LAT1 (5347S; Cell Signaling
Technology) and mouse anti–b-actin (47778; Santa Cruz Biotechnology,
Dallas, Tex) or mouse anti–a-tubulin (T6199; Sigma-Aldrich) as a loading
control. Detection of LAT1, LAT2, and CD98 in cell lines (HaCaT, Caco-
2, HeLa, and J77) was also conducted in fresh lysates prepared with
supplemented RIPA buffer and with the antibodies indicated in Table E1.
All primary antibodies were detected with horseradish peroxidase–
conjugated goat anti-rabbit (Pierce, Rockford, Ill). Protein bands were
analyzed with the LAS-3000 CCD system and Image Gauge 3.4 software
(Fuji Photo Film, Tokyo, Japan).
Quantitative profile of L-Leu by using liquid
chromatography–tandem mass spectrometry
Serum L-Leu profiles of normal (WT) and immunocompromised
(Rag12/2) mice treated or not with IMQ (for 5 days, 50 mg/d) were
measured by using liquid chromatography–tandem mass spectrometry.
Serum samples were obtained from at least 20 animals per genotype (10
healthy control mice and 10 mice with psoriasis) after 60 minutes of coag-
ulation at 48C and were immediately stored at 2808C until use. Stock so-
lutions of leucine (Sigma) and 13C11-Trp (Cambridge Isotope
Laboratories, Tewksbury, Mass) were prepared in water (LC/MS grade)
at 1000 ppm and used as an external standard and an internal standard,
respectively.
Amino acid uptake assays
Naive CD4 T cells obtained from LAT1WT, LAT1DRgt, and LAT1DCD4
mice were cultured (1 3 106 cells/mL) in RPMI medium for 24 hours
in the presence of anti-CD3 (5 mg/mL) and used to test amino acid uptake
in the presence of LAT1 inhibitors. The 3H-radiolabeled amino acids
L-phenylalanine and L-Leu (PerkinElmer, Waltham, Mass) were added
(0.5 mCi/ml) in HBSS (Gibco, Carlsbad, Calif) at a final extracellular
L-Leu concentration of 5 mmol/L. Amino acid uptake was measured at
60 minutes at 378C. Incubation with the LAT1 inhibitors JPH203
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(10 mmol/L) and 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid
(40 mmol/L) was done 10 minutes before addition of radioactivity. Uptake
was stopped by addition of 20 mmol/L cold L-Leu to quench L-System. At
the end of the assay period, cells were harvested onto glass-fiber filters
using a Tomtec 96-well parallel harvester (Tomtec, Hamden, Conn).
B-radioactivity was counted in a Beckman LS 6500 Multi-Purpose
Scintillation Counter (Beckman Coulter, Fullerton, Calif). At least 6
replicates were assessed for each data point.
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FIG E1. LAT2 and LAT3 expression is detected in the epidermal layer in patients with psoriasis. A, LAT2
detection by means of immunohistochemistry (upper) and immunofluorescence (bottom) in skin biopsy
specimens from healthy donors (left) and patients with psoriasis (right). B, LAT1, LAT2, and CD98 detection
by means of Western blotting in nonreduced conditions in 10 mg of total protein from different types of cell
lines and primary human CD4 T cells (both naive and activated). C, Histograms and values of mean
fluorescence intensity of LAT1 (left) and LAT2 (right) expression in LAT1DK5 and LAT1WT keratinocytes after
IMQ application. D, LAT3 detection by means of immunofluorescence in human skin samples. LAT2 and
LAT3 signals are shown in green, and nuclei were stained with 49-6-diamidino-2-phenylindole
dihydrochloride (DAPI; blue). Scale bars 5 100 mm. At least 3 human skin samples of each condition
were simultaneously analyzed in each study. A representative experiment of at least 2 individual replicates
is shown (n5 4-5; Fig E1, C). Data are shown as means6 SEM. ns, Not significant. *P < .05 and ***P < .001,
1-way ANOVA with the Bonferroni post hoc test.
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FIG E2. Characterization of immune cells with deletion of LAT1 under the control of RORgt expression.
A, Skin Tm1 cells of RORgt-Cre2/2 and RORgt-Cre1/2 mice were identified as CD3low gdTCRlow cells,
CD4 T cells, and CD32RORgt1 innate lymphoid cells. B, Tm expression observed in CD272 gd T cells (upper)
and CD271 ab T cells (bottom) from RORgt-Cre1/2mice. C, LAT1 expression was assessed by usingWestern
blotting (left) and FC (right) in activated CD4 T cells from LAT1WT and LAT1DRgt mice. D, Size and complexity
of cells obtained as in Fig E2, C, were evaluated by means of FC. E, L-phenylalanine uptake was assessed in
activated CD4 T cells from LAT1WT and LAT1DRgt mice. F, Expression of Tm and CCR6 in skin CD4 T cells,
dermal gd T cells (gdlow), and epidermal gd T cells (DETC) in LAT1WT and LAT1DRgt mice are shown. Absolute
numbers are shown (bottom). A representative experiment of 2 is shown (n 5 3-4 [Fig E2, A-D] or n 5 6
[Fig E2, E]). A pool of 2 independent experiments is shown (n 5 4 [Fig E2, F]). Data are shown as
means 6 SEMs. ns, Not significant. ***P < .001, 2-way ANOVA with the Bonferroni post hoc test
(Fig E2, E and F).
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FIG E3. LAT1 expression in IL-171 gd T cells controls the IL-23–induced psoriasis model. A, Dot plots of
lymph node gd T cells fromWTmice after IMQ. Expression of LAT1 in CD272IL-171 cells is shown (dot plots)
and compared with CD271 gd T cells (histograms and bars). B, Ear thickness of LAT1DRgt and LAT1WT mice
assessed after IL-23 intradermal injections. C, Transcriptional levels of indicated genes in the skin of mice
treated with PBS or IL-23. D, Representative density plots and density values of neutrophils (Ly6G1) and
macrophages (CD641) infiltrating the skin of mice treated or not with IL-23. A representative experiment
of 2 individual replicates is shown (n 5 5-6). Data are shown as means 6 SEMs. ns, Not significant.
*P < .05 and **P < .01, 2-tailed unpaired Student t test (Fig E3, A and B) and 1-way ANOVA with the
Bonferroni post hoc test (Fig E3, C and D).
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FIG E4. Deletion of LAT1 in CD4 T cells prevents TH17 differentiation.A, LAT1 expression detected bymeans
of Western blotting (left) and FC (right) in activated CD4 T cells. B L-Leu uptake assessed in activated CD4 T
cells. C, Absolute numbers of gd (upper left) and CD272 gd (upper right) T cells and frequency of Vg41d41 T
cells (bottom left) and Vd41Ki-671 cells (bottom right) in lymph nodes. D, Transcriptional levels of indicated
genes in gd T cells from lymph nodes. E, Density plots of mouse TH17 cells after PMA/ionomycin stimulation
(upper). Frequencies of IL-17– and IL-22–secreting cells (middle) and cytokine levels (ELISA; bottom) are
shown. F, Human TH17 cells were obtained in the presence of JPH203 or its vehicle. Representative dot plots
after PMA/ionomycin stimulation (upper) and frequencies of IL-17– and IFN-g–secreting cells (bottom) are
shown. A representative experiment of 2 is shown (n 5 3 [Fig E4, A]; n 5 5-6 [Fig E4, B and E]; n 5 10
[Fig E4, F]). A pool of 2 independent experiments is shown (n 5 4 [Fig E4, C and D]). Data are shown as
means 6 SEMs. ns, Not significant. *P < .05, **P < .01, and ***P < .001, 2-way ANOVA with the Bonferroni
post hoc test (Fig E4, B), 1-way ANOVA with the Bonferroni post hoc test (Fig E4, C and D), and 2-tailed un-
paired (Fig E4, E) and paired (Fig E4, F) Student t tests.
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FIG E5. Effects of the LAT1 inhibitor JPH203 in immune cells. A, Transcriptional levels of the indicated
genes induced in skin-draining lymph node after IMQ. B, Density plots (left) of the frequency of Vd41 (upper)
and Ki-671Vd41 T cells (bottom) from the dermal gd T-cell population. Frequency values are shown at right.
C, Dot plots (left) of live human gd T cells expanded in vitro with zoledronate. Values in dot plots indicate
total numbers of cells detected in culture after incubation with DMSO or JPH203 normalized by the number
of beads. The effect of JPH203 in total gd T cells obtained from each patient (n 5 8 patients) is shown
(middle). Representative western blot of purified gd T cells from one patient to analyze the LAT1-CD98
amino acid complex is shown (right). A representative experiment of 2 is shown (n 5 4-5 per group).
Data are shown as means 6 SEMs. ns, Not significant. *P < .05, **P < .01, and ***P < .001, 1-way ANOVA
with the Bonferroni post hoc test (Fig E5, A and B) and the 2-tailed paired Student t test (Fig E5, C).
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FIG E6. LAT1 inhibition controls gd T-cell proliferation and IL-17 secretion independently of AHR
expression. AHR1/2 and AHR2/2 mice received IMQ in the ear and were injected with Brefeldin A before
death. A, Representative dot plots (left) and total numbers (right and upper) of CD272 gd T cells detected
in lymph nodes. Frequencies of CD272 Vg41d41 T cells (gated on CD272 gd T cells) in lymph nodes are
also shown (right and bottom). B, Total numbers of CD272Vg41d41 (left) and CD272Vg41d42 (right)
T cells producing IL-17 are shown. Data pools of 2 independent experiments (n 5 4) are represented.
Data are shown as means 6 SEMs. ns, Not significant. **P < .01 and ***P < .001, 1-way ANOVA with the
Bonferroni post hoc test.
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TABLE E1. List of used antibodies
Specificity Reactivity Clone Origin Dilution Catalog no.
CCR6 Mouse 29-2L17 BioLegend, San Diego, Calif 1:200 129818
CD3e Mouse 145-2C11 BD Biosciences, San Jose, Calif 1:200 553066
CD4 Mouse RM4-5 BD Biosciences 1:200 20-0042
CD8 Mouse 53-6.7 BioLegend 1:200 100766
CD11b Mouse M1/70 BD Biosciences 1:200 553310
CD11c Mouse HL3 BD Biosciences 1:200 557401
CD27 Mouse LG.7F9 eBioscience, San Diego, Calif 1:200 25-0271-82
CD45.2 Mouse 104 BD Biosciences 1:200 560696
CD64 Mouse X54-5/7.1 BD Biosciences 1:200 558539
CD98 Mouse RL388 BioLegend 1:200 128210
CD98 Human, mouse H300 Santa Cruz Biotechnology, Dallas, Tex 1:500 sc-9160
LAT1 Mouse H-75 Santa Cruz Biotechnology 1:50 sc-134994
aCD16/aCD32 Mouse 2.4G2 Tonbo Biosciences, San Diego, Calif 1:200 70-0161
IL-17A Mouse TC11-18H10 BD Biosciences 1:100 559502
IL-22 Mouse IL22JOP eBioscience 1:100 17-7222-82
Ki-67 Mouse B56 BD Biosciences 1:100 558615
Ly6C Mouse AL-21 BD Biosciences 1:200 560525
Ly6G Mouse 1A8 BD Biosciences 1:200 551461
pS6 (Ser235/236) Mouse D57.2.2E Cell Signaling, Danvers Mass 1:100 8520S
TCRab Mouse H57-597 BD Biosciences 1:200 109220
TCRgd Mouse GL3 BioLegend 1:200 118118
TCR-Vd4 Mouse GL2 BioLegend 1:200 134905
TCR-Vg4 Mouse UC3-10A6 BioLegend 1:200 137704
SLC7A5 Human pAb Sigma-Aldrich, St Louis, Mo 1:200 HPA052673
SLC7A8 Human, mouse pAb Sigma-Aldrich 1:200 HPA051950
SLC43A1 Human pAb Sigma-Aldrich 1:200 HPA01882
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TABLE E2. Sequences of primers
Gene Specie Forward primer Reverse primer
Actb Mouse CAGAAGGAGATTACTGCTCTGGCT TACTCCTGCTTGCTGATCCACATC
Ccl20 Mouse ACTGTTGCCTCTCGTACATACA GAGGAGGTTCACAGCCCTTTT
Ccr6 Mouse ATGCGGTCAACTTTAACTGTGG CCCGGAAAGATTTGGTTGCCT
Gapdh Mouse AGCTTGTCATCAACGGGAAG TTTGATGTTAGTGGGGTCTCG
Hprt Mouse GCAGTACAGCCCCAAAATGG GGTCCTTTTCACCAGCAAGCT
Ifng Mouse ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCT
Il10 Mouse GCTCTTACTGACTGGCATGAC CGCAGCTCTAGGAGCATGTG
Il17a Mouse TTTAACTCCCTTGGCGCAAAA CTTTCCCTCCGCATTGACAC
Il22 Mouse ATGAGTTTTTCCCTTATGGGGAC GCTGGAAGTTGGACACCTCAA
Il23 Mouse ATGCTGGATTGCAGAGCAGTA ACGGGGCACATTATTTTTAGTCT
S100a8 Mouse AAATCACCATGCCCTCTACAAG CCCACTTTTATCACCATCGCAA
S100a9 Mouse ATACTCTAGGAAGGAAGGACACC TCCATGATGTCATTTATGAGGGC
Slc3a2 Mouse GACACCGAAGTGGACATGAAA GCTCCTCCTTGGATAAGCCG
Slc7a5 Mouse CTGGATCGAGCTGCTCATC GTTCACAGCTGTGAGGAGC
J ALLERGY CLIN IMMUNOL
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